Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP

Overview

Journal J Int Assoc Provid AIDS Care

Publisher Sage Publications

Specialty Infectious Diseases

Date 2024 Dec 19

PMID 39698980

Authors

Jennifer L Glick

Danielle F Nestadt

Travis Sanchez

Kevin Li

Marissa Hannah

M Keith Rawlings

Alex R Rinehart

Supriya Sarkar

Vani Vannappagari

Affiliations

Soon will be listed here.

Abstract

We investigated men who have sex with men's (MSM) location preferences for long-acting injectable pre-exposure prophylaxis (LA-PrEP). MSM ( = 1076) who completed the 2021 American Men's Internet Survey, were currently prescribed oral PrEP, and expressed LA-PrEP interest reported location preferences for receiving LA-PrEP: healthcare provider (HCP) setting, pharmacy, or at-home. HCP settings were preferred by 60% of participants; 26% preferred home and 14% preferred pharmacy. In adjusted models, high healthcare stigma was associated with preferring pharmacy and at-home versus HCP, while high friends/family stigma was associated with preferring HCP settings versus pharmacy. Healthcare access history was associated with preference for HCP setting versus home. Being 25 to 29 or 30 to 29 years old versus 40+ was associated with preferring HCP versus home. Private insurance was associated with location preferences. Findings support the need for multiple LA-PrEP service locations to best reach MSM and highlight multiple complex factors that influence such preferences.

References

Pan S, Durvasula M, Ong J, Liu C, Tang W, Fu H . No Place Like Home? Disentangling Preferences for HIV Testing Locations and Services Among Men Who Have Sex with Men in China. AIDS Behav. 2018; 23(4):847-859. PMC: 6458980. DOI: 10.1007/s10461-018-2366-0. View

Stephenson R, Rogers E, Mansergh G, Hirshfield S, Sullivan P . Intimate Partner Violence and Preferences for Pre-exposure Prophylaxis (PrEP) Modes of Delivery Among A Sample of Gay, Bisexual, and Other Men Who Have Sex with Men. AIDS Behav. 2022; 26(7):2425-2434. PMC: 11283765. DOI: 10.1007/s10461-022-03587-8. View

Ingram D, Franco S . 2013 NCHS Urban-Rural Classification Scheme for Counties. Vital Health Stat 2. 2014; (166):1-73. View

Sison O, Baja E, Bermudez A, Quilantang M, Dalmacion G, Guevara E . Association of anticipated HIV testing stigma and provider mistrust on preference for HIV self-testing among cisgender men who have sex with men in the Philippines. BMC Public Health. 2022; 22(1):2362. PMC: 9756449. DOI: 10.1186/s12889-022-14834-x. View

Meyerson B, Emetu R, Sanders S, Bailey M, Ryder P, Armstrong J . Preferences of Gay and Bisexual Men for Pharmacy-Based HIV Testing and Over-the-Counter HIV Tests. LGBT Health. 2016; 1(3):225-8. DOI: 10.1089/lgbt.2014.0010. View

Garcia M, Harris A . PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. PLoS One. 2017; 12(9):e0184014. PMC: 5617149. DOI: 10.1371/journal.pone.0184014. View

Mitchell K, Boily M, Hanscom B, Moore M, Todd J, Paz-Bailey G . Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. Lancet Reg Health Am. 2023; 18:100416. PMC: 9950652. DOI: 10.1016/j.lana.2022.100416. View

Hawk M, Chung A, Creasy S, Egan J . A Scoping Review of Patient Preferences for HIV Self-Testing Services in the United States: Implications for Harm Reduction. Patient Prefer Adherence. 2020; 14:2365-2375. PMC: 7719302. DOI: 10.2147/PPA.S251677. View

Cahill S, Valadez R . Growing older with HIV/AIDS: new public health challenges. Am J Public Health. 2013; 103(3):e7-e15. PMC: 3673522. DOI: 10.2105/AJPH.2012.301161. View

10.

Quinn K, Dickson-Gomez J, Zarwell M, Pearson B, Lewis M . "A Gay Man and a Doctor are Just like, a Recipe for Destruction": How Racism and Homonegativity in Healthcare Settings Influence PrEP Uptake Among Young Black MSM. AIDS Behav. 2018; 23(7):1951-1963. PMC: 6571052. DOI: 10.1007/s10461-018-2375-z. View

11.

Tolley E, Zangeneh S, Chau G, Eron J, Grinsztejn B, Humphries H . Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020; 24(9):2520-2531. PMC: 7423859. DOI: 10.1007/s10461-020-02808-2. View

12.

John S, Rendina H, Grov C, Parsons J . Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence. PLoS One. 2017; 12(12):e0189794. PMC: 5744975. DOI: 10.1371/journal.pone.0189794. View

13.

McKirnan D, Du Bois S, Alvy L, Jones K . Health care access and health behaviors among men who have sex with men: the cost of health disparities. Health Educ Behav. 2012; 40(1):32-41. DOI: 10.1177/1090198111436340. View

14.

Bonacci R, Smith D, Ojikutu B . Toward Greater Pre-exposure Prophylaxis Equity: Increasing Provision and Uptake for Black and Hispanic/Latino Individuals in the U.S. Am J Prev Med. 2021; 61(5 Suppl 1):S60-S72. PMC: 8668046. DOI: 10.1016/j.amepre.2021.05.027. View

15.

Crawford N, Josma D, Morris J, Hopkins R, Young H . Pharmacy-based pre-exposure prophylaxis support among pharmacists and men who have sex with men. J Am Pharm Assoc (2003). 2020; 60(4):602-608. PMC: 7387144. DOI: 10.1016/j.japh.2019.12.003. View

16.

Henderson M, Schmidt H, Chitembo L, Peralta H, Alaama A, Johnson C . The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery. AIDS Behav. 2023; 27(11):3755-3766. PMC: 10589125. DOI: 10.1007/s10461-023-04093-1. View

17.

Maloney K, Le Guillou A, Driggers R, Sarkar S, Anderson E, Malik A . Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model. J Infect Dis. 2020; 223(1):72-82. PMC: 7781468. DOI: 10.1093/infdis/jiaa552. View

18.

Pinto R, Hall E, Tomlin R . Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start. J Assoc Nurses AIDS Care. 2023; 34(2):216-220. PMC: 9951790. DOI: 10.1097/JNC.0000000000000386. View

19.

Thomson K, Hillier-Brown F, Walton N, Bilaj M, Bambra C, Todd A . The effects of community pharmacy-delivered public health interventions on population health and health inequalities: A review of reviews. Prev Med. 2019; 124:98-109. DOI: 10.1016/j.ypmed.2019.04.003. View

20.

Ojikutu B, Bogart L, Mayer K, Stopka T, Sullivan P, Ransome Y . Spatial Access and Willingness to Use Pre-Exposure Prophylaxis Among Black/African American Individuals in the United States: Cross-Sectional Survey. JMIR Public Health Surveill. 2019; 5(1):e12405. PMC: 6378549. DOI: 10.2196/12405. View